These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 14707409)

  • 1. How a sequential design would have affected the GAIN International Study of gavestinel in stroke.
    Bolland K; Weeks A; Whitehead J; Lees KR;
    Cerebrovasc Dis; 2004; 17(2-3):111-7. PubMed ID: 14707409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gavestinel produces no benefit for stroke patients, study finds.
    Clin Resour Manag; 2001 Nov; 2(11):173-5, 161. PubMed ID: 11727452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NXY-059: a hopeful sign in the treatment of stroke.
    Hess DC
    Stroke; 2006 Oct; 37(10):2649-50. PubMed ID: 16946156
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline.
    Bolland K; Whitehead J; Cobo E; Secades JJ
    Pharm Stat; 2009; 8(2):136-49. PubMed ID: 18637642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gavestinel. GV 150526, GV 150526A.
    Drugs R D; 1999 Jan; 1(1):23-4. PubMed ID: 10565975
    [No Abstract]   [Full Text] [Related]  

  • 6. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators.
    Lees KR; Asplund K; Carolei A; Davis SM; Diener HC; Kaste M; Orgogozo JM; Whitehead J
    Lancet; 2000 Jun; 355(9219):1949-54. PubMed ID: 10859040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotection in vascular dementia.
    Martínez-Vila E; Murie-Fernández M; Gállego Pérez-Larraya J; Irimia P
    Cerebrovasc Dis; 2006; 21 Suppl 2():106-17. PubMed ID: 16651821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the Glycine Antagonist Gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI Substudy.
    Warach S; Kaufman D; Chiu D; Devlin T; Luby M; Rashid A; Clayton L; Kaste M; Lees KR; Sacco R; Fisher M;
    Cerebrovasc Dis; 2006; 21(1-2):106-11. PubMed ID: 16340185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future of neuroprotective drugs in doubt.
    Birmingham K
    Nat Med; 2002 Jan; 8(1):5. PubMed ID: 11786882
    [No Abstract]   [Full Text] [Related]  

  • 10. Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies.
    Haley EC; Thompson JL; Levin B; Davis S; Lees KR; Pittman JG; DeRosa JT; Ordronneau P; Brown DL; Sacco RL;
    Stroke; 2005 May; 36(5):1006-10. PubMed ID: 15831831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods.
    Whitehead A; Sooriyarachchi MR; Whitehead J; Bolland K
    Stat Med; 2008 May; 27(10):1646-66. PubMed ID: 17886243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximizing Patient Recruitment and Retention in a Secondary Stroke Prevention Clinical Trial: Lessons Learned from the STAND FIRM Study.
    Thayabaranathan T; Cadilhac DA; Srikanth VK; Fitzgerald SM; Evans RG; Kim J; Gerraty RP; Phan TG; Bladin CF; Nelson MR; Frayne JH; Thrift AG
    J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1371-80. PubMed ID: 27009610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interim analyses].
    Kramar A; Paoletti X
    Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential designs for clinical trials in amyotrophic lateral sclerosis.
    Groeneveld GJ; van der Tweel I; Wokke JH; van den Berg LH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Dec; 5(4):202-7. PubMed ID: 15799547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 3: Design considerations.
    Ball G; Silverman MH
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S8-10. PubMed ID: 21664988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BMS-204352 (Bristol Myers Squibb).
    Mackay KB
    Curr Opin Investig Drugs; 2001 Jun; 2(6):820-3. PubMed ID: 11572663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.